Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Ye Hua
Ye Hua
BioNova Pharmaceuticals

Ye Hua, MD, MPH is the founder and CEO of BioNova Pharmaceuticals, a start-up biotech company that is focused on new drug development and regulatory registration to fill the gap of unmet medical needs in oncology and other diseases. Prior to building up BioNova, he was Senior VP, Head of Clinical Development and Regulatory Affairs at Hutchison MediPharm, a leading R&D company in oncology and autoimmune diseases. Managing the clinical and regulatory organization, Dr. Hua is responsible for advancing clinical development pipeline and registering new drugs in China and ex-China. Under his leadership, the clinical development programs have grown from 5 small molecules in 7 Phase 1 oncology clinical trials to 8 small molecules in over 30 Phase 1-3 clinical trials in oncology and immunology in China, Australia, and the USA. Most recently, Dr. Hua led fruquintinib NDA submission in mCRC indication via MAH policy and received NMPA approval. Native from Shanghai, Dr. Hua graduated from Fudan University Shanghai Medical College in 1992. He worked as a cancer epidemiologist at Shanghai Cancer Institute between 1992 and 1996, and then went to McGill University in Montreal Canada to pursue a Master Degree in cancer epidemiology. Dr. Hua is a senior clinical research physician who has over seventeen years’ global clinical development and new drug registration experience in the pharmaceutical industry. He started his career in the pharmaceutical industry as a biostatistician at Pharmacia & Upjohn in 1999, and worked through the rank in biostatistics. His most significant achievement being the statistical team leader for the pivotal Phase 3 RA registration trial of Humira that won regulatory approval in the US and EU. Often contributed to clinical programs beyond his role in statistics, Dr. Hua was well recognized and greatly appreciated by cross-functional development teams. In 2004, one year after joining Novartis, Dr. Hua successfully switched career track back to clinical. Being a medical monitor, he led a number of global Phase II/III registration trials in osteoarthritis, osteoporosis, infectious diseases, oncology and hematology disease areas. As clinical project leader, Dr. Hua contributed to the regulatory approval and life-cycle management for Reclast/Aclasta, Prexige, Zometa, Femara, Proleukin and Cardioxane in the US and EU. His last job in the US was Senior Director, Global Clinical Development, Celgene Corporation where he led several global clinical teams for Revlimid and Pomalyst NDA/sNDA in multiple myeloma indication, and eventually obtained regulatory approval in the US and EU. In addition, he led clinical subteam executed registration trials for Revlimid and Pomalyst in China, and successfully obtained Revlimid regulatory approval in multiple myeloma indication.

Allied Academies Global Conference Directory

Mail us at

Program Enquiry
More details about

Terms and Conditions

Cancellation, Postponement and Transfer of Registration

All cancellations or modifications of registration must be made in writing to

Cancellation Policy

If Allied Academies cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of cancellation.


If Allied Academies Ltd postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied Academies event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization, if registered person is unable to attend the event. Transfers must be made by the registered person in writin Details must be included the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied Academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if it is intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied Academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied Academies, including the inability to obtain a visa.

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

Before 60 days of the conference: Eligible for Full Refund less $100 service Fee

Within 60-30 days of Conference: Eligible for 50% of payment Refund

Within 30 days of Conference: Not eligible for Refund

Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied Academies Ltd will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.


Authorization Policy

Copyright © 2020-2021 Allied Academies, All Rights Reserved.